Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer

Creative Commons License

Soydal Ç., Araz M., Ürün Y., Nak D., Özkan E., Küçük N. Ö.

QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.65, no.3, pp.282-286, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 65 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.23736/s1824-4785.19.03165-0
  • Journal Name: QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Page Numbers: pp.282-286
  • Keywords: Prostatic neoplasms, Prostate-specific antigen, Survival, RADIOLIGAND THERAPY, RADIATION-DOSIMETRY, PSMA
  • Ankara University Affiliated: Yes

Abstract

BACKGROUND: This study aims to analyze the prognostic importance of serum prostate specific antigen (PSA) response in patients who received radioligand therapy (RLT) with Lu-177 Prostate-specific membrane antigen (PSMA) for their castration-resistant prostate cancer.